Technology area: Biotechnology & Pharmaceuticals
12 pending office actions • 3 clients • 12 examiners • 11 art units • 0 of 12 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
POLSINELLI PC - UTSW has 11 pending office actions in Biotechnology & Pharmaceuticals and 263 career applications. The profile shows a focused institutional application history and an active docket in biotechnology and pharmaceutical prosecution.
The resolved allowance rate is 57.14%, and the average is 1.63 office actions per allowance. The outcome rate indicates that resolved matters reached allowance in a limited share of the recorded portfolio, while the action average suggests that matters reaching allowance generally did so with relatively limited recorded office-action activity. Clients should consider both the outcome measure and the narrower examination path reflected by the average.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (17%) |
| §103 only | 1 (8%) |
| §102 only | 1 (8%) |
| §112 only | 3 (25%) |
| Multi-statute (no §101) | 5 (42%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEMIEUX, IAN L | 1 | 86.8% | +9.1% |
| BERRY, LAYLA D | 1 | 66.0% | +9.0% |
| COUGHLIN, MATTHEW P | 1 | 71.3% | +12.5% |
| TSUI, YUNG-SHENG M | 1 | 66.5% | +6.3% |
| CHERNYSHEV, OLGA N | 1 | 54.5% | +34.0% |
| GODDARD, LAURA B | 1 | 50.8% | +13.6% |
| KINSEY WHITE, NICOLE ERIN | 1 | 58.1% | +16.5% |
| BAILEY, STEVEN WILLIAM | 1 | 31.6% | +15.2% |
| CHANDRA, GYAN | 1 | 71.3% | +27.5% |
| RITCHIE, HADEN MATTHEW | 1 | 73.4% | +33.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18271173 | ENGINEERED STABLE ACE2 PROTEIN VARIANTS AS ANTIVIRAL NEBULIZED THERAPEUTICS | CHANDRA, GYAN | 70d |
| 18784134 | METHODS FOR HIGH-PERFORMANCE ELECTRON MICROSCOPY | LEMIEUX, IAN L | — |
| 18730565 | COMPOSITIONS AND METHODS OF REGENERATING HEART TISSUES WITH AMINOGLYCOSIDES | BERRY, LAYLA D | — |
| 18686802 | BETA ADRENERGIC RECEPTOR COMPOSITIONS AND METHODS OF USE THEREOF | COUGHLIN, MATTHEW P | — |
| 18409612 | METHODS AND COMPOSITIONS FOR MUTAGENESIS SCREENING IN MAMMALIAN CELLS | TSUI, YUNG-SHENG M | — |
| 18561044 | POLY-ADP RIBOSE (PAR) TRACKER OPTIMIZED SPLIT-PROTEIN REASSEMBLY PAR DETECTION REAGENTS | GODDARD, LAURA B | — |
| 18469022 | COMPUTATIONAL SYSTEM AND METHOD FOR DIAGNOSIS, PROGNOSIS, AND THERAPEUTICS OF CANCER PATIENTS USING SPATIAL-TEMPORAL TISSUE ARCHITECTURAL PROPERTIES | BAILEY, STEVEN WILLIAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18271173 | ENGINEERED STABLE ACE2 PROTEIN VARIANTS AS ANTIVIRAL NEBULIZED THERAPEUTICS | CHANDRA, GYAN | 70d |
| 18686802 | BETA ADRENERGIC RECEPTOR COMPOSITIONS AND METHODS OF USE THEREOF | COUGHLIN, MATTHEW P | — |
| 18409571 | PATCHED-1 MONOCLONAL ANTIBODIES AND METHODS OF USE | CHERNYSHEV, OLGA N | — |
| 18561044 | POLY-ADP RIBOSE (PAR) TRACKER OPTIMIZED SPLIT-PROTEIN REASSEMBLY PAR DETECTION REAGENTS | GODDARD, LAURA B | — |
| 18286855 | DETECTION OF SARS-COV-2 VARIANT | KINSEY WHITE, NICOLE ERIN | — |
| 18469022 | COMPUTATIONAL SYSTEM AND METHOD FOR DIAGNOSIS, PROGNOSIS, AND THERAPEUTICS OF CANCER PATIENTS USING SPATIAL-TEMPORAL TISSUE ARCHITECTURAL PROPERTIES | BAILEY, STEVEN WILLIAM | — |
| 18196262 | TUBE SECUREMENT DEVICE AND METHODS | RITCHIE, HADEN MATTHEW | — |
| Client (Assignee) | Pending OAs |
|---|---|
| University of Texas | 10 |
| University of Alabama at Birmingham | 1 |
| University of Nebraska | 1 |
| Art Unit | Apps |
|---|---|
| 2669 | 1 |
| 1693 | 1 |
| 1626 | 1 |
| 1684 | 1 |
| 1618 | 1 |
| 1672 | 1 |
| 1687 | 1 |
| 1674 | 1 |
| 3783 | 1 |
| 1798 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18784134 | METHODS FOR HIGH-PERFORMANCE ELECTRON MICROSCOPY | The Board Of Regents Of The University Of Texas System | LEMIEUX, IAN L | 2669 | §101§112 | Non-Final OA | — | Pending | Jul 25, 2024 |
| 18730565 | COMPOSITIONS AND METHODS OF REGENERATING HEART TISSUES WITH AMINOGLYCOSIDES | The UAB Research Foundation | BERRY, LAYLA D | 1693 | §102§103 | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18686802 | BETA ADRENERGIC RECEPTOR COMPOSITIONS AND METHODS OF USE THEREOF | The Board Of Regents Of The University Of Texas System | COUGHLIN, MATTHEW P | 1626 | §103§112 | Non-Final OA | — | Pending | Feb 26, 2024 |
| 18409612 | METHODS AND COMPOSITIONS FOR MUTAGENESIS SCREENING IN MAMMALIAN CELLS | The Board Of Regents Of The University Of Texas System | TSUI, YUNG-SHENG M | 1684 | §102§103 | Non-Final OA | — | Pending | Jan 10, 2024 |
| 18409571 | PATCHED-1 MONOCLONAL ANTIBODIES AND METHODS OF USE | The Board Of Regents Of The University Of Texas System | CHERNYSHEV, OLGA N | §112 | Non-Final OA | — | Pending | Jan 10, 2024 | |
| 18561044 | POLY-ADP RIBOSE (PAR) TRACKER OPTIMIZED SPLIT-PROTEIN REASSEMBLY PAR DETECTION REAGENTS | The Board Of Regents Of The University Of Texas System | GODDARD, LAURA B | 1618 | §102§103§112 | Non-Final OA | — | Pending | Nov 15, 2023 |
| 18286855 | DETECTION OF SARS-COV-2 VARIANT | The Board Of Regents Of The University Of Texas System | KINSEY WHITE, NICOLE ERIN | 1672 | §112 | Non-Final OA | — | Pending | Oct 13, 2023 |
| 18469022 | COMPUTATIONAL SYSTEM AND METHOD FOR DIAGNOSIS, PROGNOSIS, AND THERAPEUTICS OF CANCER PATIENTS USING SPATIAL-TEMPORAL TISSUE ARCHITECTURAL PROPERTIES | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | BAILEY, STEVEN WILLIAM | 1687 | §101§102§103 | Non-Final OA | — | Pending | Sep 18, 2023 |
| 18271173 | ENGINEERED STABLE ACE2 PROTEIN VARIANTS AS ANTIVIRAL NEBULIZED THERAPEUTICS | The Board Of Regents Of The University Of Texas System | CHANDRA, GYAN | 1674 | §102§112 | Final Rejection | 70d | Pending | Jul 06, 2023 |
| 18196262 | TUBE SECUREMENT DEVICE AND METHODS | The Board Of Regents Of The University Of Texas System | RITCHIE, HADEN MATTHEW | 3783 | §102 | Non-Final OA | — | Pending | May 11, 2023 |
| 18249864 | HIGH THROUGHPUT CELL MIGRATION ASSAY PLATES AND METHODS OF FABRICATION | The Board Of Regents Of The University Of Texas System | HANDY, DWAYNE K | 1798 | §103 | Final Rejection | — | Pending | Apr 20, 2023 |
| 18249661 | METHODS FOR GENERATING FORMATIVE PLURIPOTENT STEM CELLS COMPETENT FOR DIRECT PRIMORDIAL GERM CELL INDUCTION | The Board Of Regents Of The University Of Texas System | MONTANARI, DAVID A | 1632 | §112 | Final Rejection | 8d overdue | Pending | Apr 19, 2023 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial57.1% of resolved applications prosecuted by Polsinelli Pc - Utsw were allowed, across 263 applications in USPTO records.
1.63 office actions per allowed application on average.
12 pending office actions as of October 2026, for 3 clients, before 12 examiners in 11 art units.
